Miliary tuberculosis medical therapy

Jump to navigation Jump to search

Miliary tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Miliary tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Miliary tuberculosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Miliary tuberculosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Miliary tuberculosis medical therapy

CDC on Miliary tuberculosis medical therapy

Miliary tuberculosis medical therapy in the news

Blogs on Miliary tuberculosis medical therapy

Directions to Hospitals Treating Miliary tuberculosis

Risk calculators and risk factors for Miliary tuberculosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

See: Tuberculosis treatment

Miliary TB is a serious condition; untreated miliary TB is almost always fatal. About 25% of patients with miliary TB also have tuberculous meningitis. The standard treatment recommended by the WHO is with isoniazid and rifampicin for six months, as well as ethambutol and pyrazinamide for the first two months. If there is evidence of meningitis, then treatment is extended to twelve months. The US guidelines recommend nine months of treatment. Common medication side effects a patient may have such as inflammation of the liver if a patient is taking pyrazinamide, rifampin, and isoniazid. A patient may also have drug resistance to medication, relapse, respiratory failure, and adult Respiratory Distress Syndrome[1]

References

  1. Dugdale, David, "Disseminated Tuberculosis" http://www.nlm.nih.gov/medlineplus/ency/article/000624htm, December 3, 2008.

Template:WH Template:WS